NO323359B1 - Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. - Google Patents

Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. Download PDF

Info

Publication number
NO323359B1
NO323359B1 NO19983456A NO983456A NO323359B1 NO 323359 B1 NO323359 B1 NO 323359B1 NO 19983456 A NO19983456 A NO 19983456A NO 983456 A NO983456 A NO 983456A NO 323359 B1 NO323359 B1 NO 323359B1
Authority
NO
Norway
Prior art keywords
bacteriophage
phage
bacterial
antibody
protein
Prior art date
Application number
NO19983456A
Other languages
English (en)
Norwegian (no)
Other versions
NO983456L (no
NO983456D0 (no
Inventor
Sven Mardh
Original Assignee
Phagen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phagen Ab filed Critical Phagen Ab
Publication of NO983456D0 publication Critical patent/NO983456D0/no
Publication of NO983456L publication Critical patent/NO983456L/no
Publication of NO323359B1 publication Critical patent/NO323359B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/14011Details ssDNA Bacteriophages
    • C12N2795/14111Inoviridae
    • C12N2795/14132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19983456A 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. NO323359B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
PCT/SE1997/000172 WO1997029185A1 (en) 1996-02-06 1997-02-05 Recombinant phages

Publications (3)

Publication Number Publication Date
NO983456D0 NO983456D0 (no) 1998-07-27
NO983456L NO983456L (no) 1998-10-06
NO323359B1 true NO323359B1 (no) 2007-04-10

Family

ID=20401289

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19983456A NO323359B1 (no) 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel.

Country Status (16)

Country Link
EP (1) EP0889955B1 (zh)
JP (1) JP4015195B2 (zh)
KR (1) KR100459638B1 (zh)
CN (1) CN1125174C (zh)
AT (1) ATE266091T1 (zh)
AU (1) AU712767B2 (zh)
CA (1) CA2244792A1 (zh)
DE (1) DE69728975T2 (zh)
ES (1) ES2221033T3 (zh)
HU (1) HUP9901242A3 (zh)
IL (2) IL125645A0 (zh)
NO (1) NO323359B1 (zh)
NZ (1) NZ331580A (zh)
RU (1) RU2215032C2 (zh)
SE (1) SE506771C2 (zh)
WO (1) WO1997029185A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
EP1187914B1 (en) 1999-06-14 2005-05-25 Genentech, Inc. A structured peptide scaffold for displaying turn libraries on phage
DE60113851T2 (de) * 2000-07-25 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bakteriophage mit breitem wirtsspektrum
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
KR20040036176A (ko) * 2002-10-23 2004-04-30 (주)엘피스바이오텍 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
CN102296051B (zh) * 2011-03-07 2014-09-17 江苏省农业科学院 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用
RU2503716C1 (ru) * 2012-09-27 2014-01-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN106198523A (zh) * 2016-07-06 2016-12-07 哈尔滨贝贝凯尔科技发展有限公司 微量元素检测试纸及其制备方法
US20200271657A1 (en) 2017-10-04 2020-08-27 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
CN112739416B (zh) * 2018-12-27 2024-09-06 国立大学法人东海国立大学机构 宿主细菌特异性纳米粒子
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager

Also Published As

Publication number Publication date
AU712767B2 (en) 1999-11-18
WO1997029185A1 (en) 1997-08-14
NO983456L (no) 1998-10-06
KR19990082041A (ko) 1999-11-15
EP0889955B1 (en) 2004-05-06
SE506771C2 (sv) 1998-02-09
CA2244792A1 (en) 1997-08-14
JP4015195B2 (ja) 2007-11-28
CN1125174C (zh) 2003-10-22
IL125645A0 (en) 1999-04-11
EP0889955A1 (en) 1999-01-13
AU1681797A (en) 1997-08-28
DE69728975D1 (de) 2004-06-09
DE69728975T2 (de) 2005-05-04
NO983456D0 (no) 1998-07-27
NZ331580A (en) 1999-09-29
ATE266091T1 (de) 2004-05-15
KR100459638B1 (ko) 2005-02-24
HUP9901242A2 (hu) 1999-07-28
RU2215032C2 (ru) 2003-10-27
JP2000505648A (ja) 2000-05-16
SE9600434L (sv) 1997-08-07
SE9600434D0 (sv) 1996-02-06
ES2221033T3 (es) 2004-12-16
HUP9901242A3 (en) 2000-03-28
CN1210558A (zh) 1999-03-10
IL125645A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
Cao et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth
Steiner et al. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display
EP0889955B1 (en) Recombinant phages
RU2412249C2 (ru) Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
CN111961133A (zh) 一种针对新冠病毒SARS-CoV-2棘突蛋白非RBD区的单克隆抗体及其应用
US20020044922A1 (en) Recombinant phages
Lester et al. Characterization of H elicobacter pylori HP 0231 (DsbK): role in disulfide bond formation, redox homeostasis and production of H elicobacter cystein‐rich protein HcpE
CN106008710B (zh) 一种猪源性抗产肠毒素大肠杆菌K88 FaeG蛋白的单链抗体及其制备方法
Aikawa et al. Single-chain variable fragment (scFv) targeting streptolysin O controls group A Streptococcus infection
Kwaśnikowski et al. Multivalent display system on filamentous bacteriophage pVII minor coat protein
US5494672A (en) Pseudomonas peptide composition and method
US6497874B1 (en) Recombinant phages
Sabarth et al. Identification of Helicobacter pylori surface proteins by selective proteinase K digestion and antibody phage display
JP2005508395A (ja) 炭疽菌毒素を検出および中和するための組換え抗体
CN104531730B (zh) 产气荚膜梭菌α毒素人源化单链抗体8B
CN106632670A (zh) 一种猪源性抗猪传染性胃肠炎病毒的单链抗体及其制备方法
MXPA06011501A (es) Peptidos terapeuticos.
Pokorny et al. Inhibition of Cryptosporidium parvum infection of a mammalian cell culture by recombinant scFv antibodies
CN108976289B (zh) 用于预防和治疗肠致病大肠杆菌感染的肽段
AU5328599A (en) Gastrointestinal bacterial antibody factories
Ojobor The Noncontractile Phage Tail-Like Bacterial Killing Nanomachines–Characterizing the Specificity Determinants of the F-Pyocins of Pseudomonas aeruginosa
JP2007236237A (ja) ベクターライブラリーの製造方法、人工ポリクローナル抗体の製造方法、及び医薬組成物の製造方法
Tout et al. Phage display and bacterial expression of a recombinant Fab specific for Pseudomonas aeruginosa serotype O6 lipopolysaccharide
Naylor Development of a Dusky kob scFv gene phage display library for the discovery of antibodies to Brome mosaic virus-a proxy for a novel, emerging fish pathogen
CN118344443A (zh) 一种增强噬菌体对肠黏膜黏附能力的蛋白a